The first and only
for the treatment of nocturia due to
nocturnal polyuria (NP) in adults who awaken at least 2 times per night to void1
NOCDURNA dissolves rapidly and starts working quickly1
Sublingual tablet dissolves
in seconds—without water1,2
Patients taking NOCDURNA wake up fewer times to void
The majority of patients had their nightly voids cut by 1/31*‡
95% CI [1.36, 3.41] (N=118)
95% CI [1.30, 3.14] (N=102)
In a study where nocturia patients averaged 3 nighttime bathroom visits1
NOCDURNA reduced nighttime voids by nearly half1
95% CI [-0.5, -0.1] (N=118)
95% CI [-0.6, -0.2] (N=102)
- Mean adjusted probability of achieving at least a 33% reduction from baseline in average number of nightly voids. 33% responder rate used to ensure a reasonable estimate of clinical benefit.
- Reduction of 1.5 voids in women and 1.3 voids in men relative from mean baselines of 2.9 in women and 3.0 in men.
- A 33% responder was defined as a subject with a decrease of at least 33% in the mean number of nocturnal voids compared to baseline.
NOCDURNA reduced and sometimes eliminated nighttime voids
Percent (%) of nights with at most 1 void1
Percent (%) of men and women with no voids1
Men taking NOCDURNA
doubled their nights
with no voids vs placebo
95% CI [4%, 14%] (N=102)
Women taking NOCDURNA
increased their nights without
voids by 19% over baseline‡
95% CI [-3%, 11%] (N=118)
- Nights without voids measured 0% at baseline and increased to 19% at the end of 3 months.
Patients taking OAB or BPH medications were also included in the clinical trials1
Antimuscarinics, α-blockers, and α-reductase inhibitors were permitted to be taken concomitantly for mild OAB or BPH1
The efficacy of NOCDURNA was established in two 3-month, randomized, double-blind, placebo-controlled, multi-center trials in adults over 18 years of age. Study 1 included 237 female patients and Study 2 included 230 male patients. Women received NOCDURNA 27.7 mcg and men received NOCDURNA 55.3 mcg. The co-primary endpoints were the change in number of nighttime voids compared to baseline and the percentage of patients who achieved a 33% reduction from baseline in the mean number of nighttime voids.1
Reference: 1. NOCDURNA [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc.
Reference: 2. Data on File: NOC002